Relugolix and Estradiol and Norethindrone

Brand names: Myfembree · Active ingredient: Relugolix, Estradiol Hemihydrate, Norethindrone Acetate

In short: MYFEMBREE is indicated for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women . MYFEMBREE is indicated for the management of moderate to severe pain associated with endometriosis in premenopausal women .

Forms & strengthsTablets: Each tablet of MYFEMBREE contains a fixed-dose combination of relugolix 40 mg, estradiol (E2) 1 mg, and norethindrone acetate (NETA) 0.5 mg. …
LabelSumitomo Pharma America, Inc
Label updatedNov 05, 2026

What is Relugolix and Estradiol and Norethindrone used for?

MYFEMBREE is indicated for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women .

MYFEMBREE is indicated for the management of moderate to severe pain associated with endometriosis in premenopausal women .

Use of MYFEMBREE should be limited to 24 months due to the risk of continued bone loss that may not be reversible .

âš  Boxed warning (FDA's strongest warning)

Estrogen and progestin combinations, including MYFEMBREE, increase the risk of thrombotic or thromboembolic disorders, including pulmonary embolism (PE), deep vein thrombosis (DVT), stroke and myocardial infarction (MI), especially in women at increased risk for these events

MYFEMBREE is contraindicated in women with current or a history of thrombotic or thromboembolic disorders and in women at increased risk for these events, including women over 35 years of age who smoke or women with uncontrolled hypertension

.

Relugolix and Estradiol and Norethindrone dosage

Exclude pregnancy .

Discontinue hormonal contraceptives

Take one tablet of MYFEMBREE orally once daily at approximately the same time, with or without food .

Start MYFEMBREE as early as possible after the onset of menses but no later than seven days after menses has started .

The recommended total duration of treatment with MYFEMBREE is 24 months .

Take the missed dose of MYFEMBREE as soon as possible the same day and then resume regular dosing the next day at the usual time.

Avoid concomitant use of MYFEMBREE with oral P-gp inhibitors. If concomitant use is unavoidable, take MYFEMBREE first and separate dosing by at least 6 hours .

How to take Relugolix and Estradiol and Norethindrone — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Thromboembolic Disorders and Vascular Events

Advise patients that use of estrogen and progestin combinations may increase the risk of venous and arterial thrombotic/thromboembolic events, especially in women at high risk for these events .

Bone Loss

Advise patients about the risk of bone loss. Advise patients that supplementary calcium and vitamin D may be beneficial if dietary intake of calcium and vitamin D is not adequate. Advise women that oral iron supplementation should not be taken at the same time as calcium and vitamin D .

Suicidal Ideation and Mood Disorders (Including Depression)

Advise patients that depression, mood disorders, and suicidal ideation may occur with MYFEMBREE use. Instruct women with new onset or worsening depression, anxiety, or other mood changes to promptly seek medical attention .

Hepatic Impairment and Transaminase Elevations

Advise women to promptly seek medical attention in case of signs or symptoms that may reflect liver injury, such as jaundice . …

Warnings & precautions

Do not take this medicine if: MYFEMBREE is contraindicated in women:

With a high risk of arterial, venous thrombotic, or thromboembolic disorders . Examples include women over 35 years of age who smoke and women who are known to have:

current or history of deep vein thrombosis or pulmonary embolism

vascular disease (e.g., cerebrovascular disease, coronary artery disease, peripheral vascular disease)

thrombogenic valvular or thrombogenic rhythm diseases of the heart (e.g., subacute bacterial endocarditis with valvular disease, or atrial fibrillation)

inherited or acquired hypercoagulopathies

uncontrolled hypertension

headaches with focal neurological symptoms or migraine headaches with aura if over 35 years of age

Who are pregnant. Exposure to MYFEMBREE early in pregnancy may increase the risk of early pregnancy loss .

With known osteoporosis, because of the risk of further bone loss .

With current or history of breast cancer or other hormone-sensitive malignancies, and with increased risk for hormone-sensitive malignancies .

With known hepatic impairment or disease .

With undiagnosed abnormal uterine bleeding.

With known anaphylactic reaction, angioedema, or hypersensitivity to MYFEMBREE or any of its components. Anaphylactoid reactions, urticaria, and angioedema have been reported .

MYFEMBREE is contraindicated in women with current or history of thrombotic or thromboembolic disorders and in women at increased risk for these events .

Discontinue MYFEMBREE immediately if an arterial or venous thrombotic, cardiovascular, or cerebrovascular event occurs or is suspected. Discontinue MYFEMBREE at least 4 to 6 weeks before surgery of the type associated with an increased risk of thromboembolism, or during periods of prolonged immobilization, if feasible. …

Relugolix and Estradiol and Norethindrone side effects

The following clinically significant adverse reactions are discussed elsewhere in the labeling:

Thromboembolic Disorders and Vascular Events

Bone Loss

Suicidal Ideation and Mood Disorders (Including Depression)

Hepatic Impairment and Transaminase Elevations

Elevated Blood Pressure

Change in Menstrual Bleeding Pattern and Reduced Ability to Recognize Pregnancy

Uterine Fibroid Prolapse or Expulsion

Alopecia

Effects on Carbohydrate and Lipid Metabolism

Hypersensitivity Reactions

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Heavy Menstrual Bleeding Associated with Uterine Leiomyomas

The safety of MYFEMBREE was evaluated in two placebo-controlled clinical trials, Study L1 (LIBERTY 1) and Study L2 (LIBERTY 2), in women with heavy menstrual bleeding associated with uterine fibroids. In these trials, women received a once daily relugolix 40-mg tablet and an over-encapsulated tablet of E2 1 mg and NETA 0.5 mg (relugolix + E2/NETA), which is equivalent to 1 tablet of MYFEMBREE. Across the two trials, 254 women received MYFEMBREE once daily for 24 weeks. Additionally, 256 women received placebo for 24 weeks, and 258 women received relugolix 40-mg monotherapy once daily for 12 weeks followed by MYFEMBREE for 12 weeks . …

Drug interactions

P-gp Inhibitors

Co-administration of MYFEMBREE with P-gp inhibitors increases the AUC and maximum concentration (Cmax) of relugolix and may increase the risk of adverse reactions associated with MYFEMBREE. Avoid use of MYFEMBREE with oral P-gp inhibitors.

If use is unavoidable, take MYFEMBREE first, separate dosing by at least 6 hours, and monitor patients for adverse reactions .

Combined P-gp and Strong CYP3A Inducers

Use of MYFEMBREE with combined P-gp and strong CYP3A inducers decreases the AUC and Cmax of relugolix, estradiol, and/or norethindrone and may decrease the therapeutic effects of MYFEMBREE. Avoid use of MYFEMBREE with combined P-gp and strong CYP3A inducers.

About this medicine

MYFEMBREE tablets for oral administration contain a fixed-dose combination of relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg as active ingredients.

Relugolix is a non-peptide small molecule, GnRH receptor antagonist. It is a white to off white to slightly yellow solid and is sparingly soluble in water. The chemical name is N-(4-{1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl}phenyl)-N-methoxyurea with the empirical formula of C29H27F2N7O5S and a molecular weight of 623.63. The structural formula is:

Estradiol (E2), an estrogen, is present as the hemihydrate (C18H24O2•½H2O) which is a white or almost white crystalline powder. Its chemical name is estra-1, 3, 5 (10)-triene-3, 17β-diol with the empirical formula of C18H24O2 and a molecular weight of 272.4. The structural formula is:

Norethindrone acetate (NETA), a progestin, is a white or yellowish-white crystalline powder. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID fc3feb73-cc84-43a8-aa32-b262460495e8. Read the full official label on DailyMed.

Related medicines

Gabapentin Meloxicam Acetaminophen and Hydrocodone Duloxetine Prednisone Ibuprofen Tramadol Cyclobenzaprine